Logo

Tekmira Prices Common Stock Offering

Oct 17, 2013
Premium

Tekmira Pharmaceuticals said this week that it has priced a public offering of 3.75 million shares of its common stock at $8 a share, for gross proceeds of $30 million.

Tekmira stock closed at $8.82 on Wednesday.

The company said that the underwriters of the offering have also been granted an option to purchase an additional 562,500 shares.

The offering is expected to close on or about Oct. 22.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Tekmira
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.